Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
Status:
Enrolling by invitation
Trial end date:
2022-05-22
Target enrollment:
Participant gender:
Summary
A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to
compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment
of sIBM
Phase:
Phase 3
Details
Lead Sponsor:
Orphazyme
Collaborators:
University College, London University of Kansas Medical Center